Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China

Overview of attention for article published in Frontiers in Cardiovascular Medicine, November 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 7 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 8,188 followers.

RT @FrontCVMedicine: New Research: Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in…

20 Nov 2022

Reply Repost Favourite

New Research: Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China: Aim To determine the pharmacoeconomics of empagliflozin for the treatment of heart failure (HF) with reduced… https://t.co/WmhdfM

20 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.